Linear and loglinear structural mean models to evaluate the benefits of an on-demand dosing regimen

Clinical Trials

Volumn 6, Issue 5, 2009, Pages 403-415

  Comtá, Laetitia ^a   Vansteelandt, Stijn ^b   Tousset, Eric ^c   Baxter, Garth ^d   Vrijens, Bernard ^c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c Pharmionic Research Center   (Belgium)

^d Wyeth Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SELECTIVITY; EPIGASTRIC PAIN; EROSIVE GASTRITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HUMANS; LINEAR MODELS; MULTICENTER STUDIES AS TOPIC; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 71049140839     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774509344777     Document Type: Article

References (28)

1. Lee J., Ellenberg J., Hirtz D., Nelson K. Analysis of clinical trials by treatment actually received: Is it really an option? Stat Med 1991; 10: 1595-1605.
2. Goetghebeur E., Pocock S. Statistical issues in allowing for noncompliance and withdrawal. Drug Inform J 1993; 27: 837-45.
3. Bellamy SL, Lin JY, Have TRT An introduction to causal modelling in clinical trials. Clin Trials 2007; 4: 58-73.
4. Sommer A., Zeger SL On estimating efficacy from clinical trials. Stat Med 1991; 10: 45-52.
5. Frangakis CE, Rubin DB Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes. Biometrika 1999; 86: 365-79.
6. Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc 1991; 86: 9-25.
7. Robins JM. Correcting for non-compliance in randomized trials using structural nested mean models. Commun Stat Theory Meth 1994; 23: 2379-2412.
8. Fisher-Lapp K., Goetghebeur E. Practical properties of some structural mean analyses of the effect of compliance in randomized trials. Control Clin Trials 1999; 20: 531-46.
9. Robins J., Rotnitzky A. Estimation of treatment effects in randomised trials with non-compliance and a dichotomous outcome using structural mean models. Biometrika 2004; 91: 763-83.
10. Vansteelandt S., Goetghebeur E. Causal inference with generalized structural mean models. J R Stat Soc B 2003; 65: 817-35.
11. Mark SD, Robins JM Estimating the causal effect of smoking cessation in the presence of confounding factors using a rank preserving structural failure time model. Stat Med 1993; 12: 1605-28.
12. Loeys T., Goetghebeur E. A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance. Biometrics 2003; 59: 100-05.
13. Greenland S., Lanes S., Jara M. Estimating effects from randomized trials with discontinuations: The need for intent-to-treat design and G-estimation. Clin Trials 2008; 5: 5-13.
14. Tanaka S., Matsuyama Y., Shiraki M., Ohashi Y. Estimating the effects of time-varying treatments: Incidence of fractures among postmenopausal Japanese women. Epidemiology 2007; 18: 529-36.
15. Vansteelandt S., Babanezhad M., Goetghebeur E. Correcting instrumental variables estimators for systematic measurement error. Stat Sinica 2009; 19: 1223-46.
16. Vrijens B., Tousset E., Rode R. et al. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol 2005; 45: 461-67.
17. Harter JG, Peck CC Chronobiology. Suggestions for integrating it into drug development. Ann N Y Acad Sci 1991; 618: 563-71.
18. Sheiner LB Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61: 275-91.
19. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-97.
20. Hernan MA, Robins M. Instruments for causal inference: An epidemiologist's dream? Epidemiology 2006; 17: 360-72.
21. Vansteelandt S., Goetghebeur E. Sense and sensitivity when correcting for observed exposures in randomized clinical trials. Stat Med 2005; 24: 191-210.
22. Newey WK, McFadden D. Large Sample Estimation and Hypothesis Testing. Handbook of Econometrics (Vol. 4). Elsevier, Amsterdam, 1994.
23. Van der Vaart AW Asymptotic Statistics. Cambridge University Press, Cambridge, 1998.
24. Efron B., Tibshirani RJ An Introduction to the Bootstrap. Chapman & Hall, San Francisco, 1993.
25. Ruppert D., Wand MP, Carroll RJ Semiparametric Regression. Cambridge Series in Statistical and Probabilities Mathematics, Cambridge, 2003.
26. Chamberlain G. Asymptotic efficiency in estimation with conditional moment restrictions. J Economet 1987; 34: 305-34.
27. Bickel PJ, Klaassen CAJ, Ritov Y., Wellner JA Efficient and Adaptive Estimation for Semiparametric Models. Springer-Verlag, New York, 1993.
28. Goetghebeur E., Lapp K. The effect of treatment compliance in a placebo-controlled trial: Regression with unpaired data. Appl Statist 1997; 46: 351-64.